Literature DB >> 3962762

Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke.

S T McCarthy, J Turner.   

Abstract

Venous thrombo-embolism is a major and often unrecognized cause of morbidity and mortality in patients after acute strokes. Three hundred and five elderly patients were randomly allocated to either control (161) or treatment (144) with 5000 units calcium heparin subcutaneously 8-hourly for two weeks. A reduction in deep-vein thrombosis rate from 72.7% in the control group to 22.2% in treatment patients was achieved. In patients who died (84), post-mortem examination to look for pulmonary emboli was performed in 71. Comparison between treated and untreated patients showed significantly fewer deaths and pulmonary emboli in the treated group. Most of the beneficial effect on mortality was seen in patients with lighter strokes. When patients with pulmonary emboli at post-mortem were excluded, there was no significant difference in the death rate in treatment (17) and control (14) groups. At post-mortem, 9.9% of the strokes were haemorrhagic (4 in the treatment and 3 in the control group). Low-dose calcium heparin given subcutaneously following acute stroke reduced the number of deep-vein thromboses, pulmonary emboli and deaths without increasing the number of haemorrhagic strokes in this study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3962762     DOI: 10.1093/ageing/15.2.84

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  24 in total

Review 1.  Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation.

Authors:  G Eymin; A K Jaffer
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  The frequency, causes and timing of death within 30 days of a first stroke: the Oxfordshire Community Stroke Project.

Authors:  J Bamford; M Dennis; P Sandercock; J Burn; C Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

Review 3.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

Review 4.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

Review 5.  The venous thrombotic risk in nonsurgical patients.

Authors:  J Bouthier
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 6.  Anticoagulant drugs in the elderly: the risks usually outweight the benefits.

Authors:  P J Scott
Journal:  BMJ       Date:  1988-11-12

Review 7.  Anticoagulant drugs in the elderly: valuable in selected patients.

Authors:  G D Lowe
Journal:  BMJ       Date:  1988-11-12

Review 8.  Care of the stroke patient: routine management to lifesaving treatment options.

Authors:  George A Lopez; Arash Afshinnik; Owen Samuels
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

9.  Management and prevention of venous thromboembolism including surgery and the pregnant state.

Authors:  Steven B Deitelzweig
Journal:  Ochsner J       Date:  2002

10.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.